Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Gorilla and King Portfolio Candidates -- Ignore unavailable to you. Want to Upgrade?

To: unclewest who wrote (13926)	1/3/2000 9:41:00 AM
From: Mike Buckley	Read Replies (1) \| Respond to of 54805

unclewest, Since I'm feeling like I'm on a roll with my requests, I'm gonna ask a huge favor of you too. A few days ago I asked 100 if s/he would mind using upper-case letters at the beginning of sentences. I (we) got a favorable response. Just as in his/her case, I love your posts and find them difficult to read. I wonder if you could do the same. And what's the chance of getting you to re-write all those old CREE posts to include upper-case letters before I soon get to them?!!!!! (Just kidding, of course.) Whatever you decide, make it a great New Year! --Mike Buckley

To: unclewest who wrote (13926)	1/3/2000 12:08:00 PM
From: Apollo	Read Replies (3) \| Respond to of 54805

Hi UnC: Thanks for the feedback on Rambus; must admit it is off my radar screen for the present, so I appreciate the update. AS for IMCL, we had a discussion here around Dec 1st on Biotech in general. My views then and now is that the High Tech arena is a target rich environment for G's & K's, with less risk than can be found in Biotech. As a physician-scientist-investigator, my impression is that developing a compound, entering Phase I trials, and finally achieving FDA approval to generating revenues.......is the equivalent of completing several marathons, strung end-to-end. This doesn't mean Biotech won't be big, or that IMCL isn't the next Amgen, just that I have decided to stick with High Tech, and the GG. IMCL is a biotech concern that is pursuing research in to treating cancer with antibodies aimed at receptors, either by inhibiting epidermal growth for squamous cell carcinoma or by inhibiting blood vessel growth with anti-angiogenesis compounds (ie, starve the tumor of blood enrichment). The former is in Phase III, the latter in Phase I. Once a compound hits Phase III, FDA approval has about a 75% chance of taking place. However, even this may take a subsequent year. Inhibiting angiogenesis (blood vessel formation, crucial to cancer growth) is an idea whose champion is here in Boston. The idea was widely disseminated by hype and poor journalism in a NY Times article a couple years ago; remember when Entremed got pumped up? In fact, the generalities and imprecision by the author of that article is another example of the dangers associated with such reckless behavior. I distinctly remember a lot of unlucky patients with cancer were driven by false hope by that one article to find out from their oncologists and the government when the "wonder drug" would be available. Reckless, uncaring. Goes to the heart of what Lindy was saying over the weekend, ie the importance of being precise, nevermind whatever "science" background one might have. The biotech market is almost prohibitively expensive: both to develop compounds, and to pay for once approved. These compounds so far approved have improved our way of life, but are "breaking the bank". And we are only at the tip of the iceberg. I have no fundamental idea of how this country will afford evolving biotech technologies under the present system of health care reimbursement. Something will have to give. Apollo